
Chinese biopharmaceutical company founded in 2015 and headquartered in Beijing, co-founded by structural biologist Shi Yigong and Zhao Renbin, listed on the Hong Kong Stock Exchange under code 9969 since March 2020 and on the Shanghai STAR Market under code 688428 since September 2022. Discovers, develops and commercialises small molecule drugs and biologics for cancer and autoimmune disease, with its Bruton tyrosine kinase inhibitor orelabrutinib as the lead marketed product alongside a pipeline covering TYK2, pan-FGFR, CD19 and other targets, supported by research centres in Beijing, Nanjing, Shanghai and the United States and a manufacturing base in Guangzhou.
查看公司简介
留下您的评分